Brief: Can-Fite Initiates Preclinical Studies Required By FDA And EMA For Registration Of Its Two Lead Drug Candidates

Can Fite Biopharma

20/04/2021 12:12

April 20 (Reuters) - Can Fite Biopharma Ltd  CANF.TA :
    * CAN-FITE INITIATES PRECLINICAL STUDIES REQUIRED BY FDA AND
EMA
FOR THE REGISTRATION OF ITS TWO LEAD DRUG CANDIDATES
    * CAN FITE BIOPHARMA LTD - PICLIDENOSON IN PHASE III FOR
PSORIASIS
& NAMODENOSON TO ENTER PIVOTAL PHASE III FOR LIVER CANCER
    * CAN FITE BIOPHARMA LTD - PHASE III STUDY OF NAMODENOSON IN
TREATMENT OF HEPATOCELLULAR CANCER IS EXPECTED TO COMMENCE IN Q4
OF 2021

Source text for Eikon:  ID:nBw72cp2Va 
Further company coverage:  CANF.TA 

 ((Reuters.Briefs@thomsonreuters.com;))